Scale up isolation of aaptamine for in vivo evaluation indicates its
neurobiological activity is linked to the delta opioid receptor
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Opioid receptors belong to the large superfamily of seven transmembrane-spanning (7TM)
G protein-coupled receptors (GPCRs). As a class, GPCRs are of fundamental physiological
importance mediating the actions of the majority of known neurotransmitters and
hormones. The Mu (µ), Delta (δ) and Kappa (MOR, DOR, KOR) opioid receptors are
particularly intriguing members of this receptor family as they are the targets involved in
many neurobiological diseases such as addiction, pain, stress, anxiety, and depression. To
date few marine natural products have been investigated for their neurobiological
activities.1 One noteworthy example involves ziconotide (1) from the cone snail Conus
magnus.2 Compound 1 was the first marine natural product approved by the FDA and is
used for the treatment of pain, marketed under the trade name Prialt® (2004).3 More
recently Hamman reported that aaptamine (2) is the first marine natural product to show in
vivo anti-depressant activity, however no mechanism of action was proposed.1,4 During a
separate collaborative screening project we profiled 96 sponge-derived extracts and
discovered that demethyl–aaptamine (3) and demethyl (oxy)–aaptamine (4) were selective
DOR agonists using an LC-MS based library of an active methanolic extract coll. no. 92553
FM as shown in Fig. 1. We speculated that the in vivo activity for 2 could thus be linked to
the DOR target and to test this hypothesis we conducted the following experiments below.
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Figure 4. Chemical validation of aaptamine (2) using: a) LC-MS-ELSD analysis with
annotations including m/z ions and b) 1H NMR data of 11308 WB H6.
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Figure 2. Extraction Scheme Flowchart of coll. no. 11308
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Figure 5. Mice were injected with saline or aaptamine (2, 40mg/kg, i.p.) and subjected to:
a forced swim test (a), a locomotor test (b) or a marble burying test (c).
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Swim sessions lasted 10min (in ambient light of 580–680lx), and were conducted in individual clear plastic cylinders (35.5cm tall × 25cm in diameter)
filled with water (26.5°C, ±0.7°C) to a depth of 20cm±1.5cm. A camera positioned on an angle to the cylinders recorded the sessions. Manual scoring
was for total immobile time during the last 6min of the session. Immobility was defined as the absence of movement, except that necessary to keep afloat.
Following the swim test, mice were placed in a locomotor chamber to assess general locomotion for 30 minutes. For the marble burying test, mice were
placed in a cage with 5 cm of wood shavings and 15 evenly spaced marbles for 20 minutes. At the end of the session, the number of marbles buried and
exposed were counted. Aaptamine (2) was effective in WT but not DOR knock out (KO) mice (* p<.05 compared to saline).

3 4

Figure 1. a) LC-MS library with annotations including m/z ions and b) Comparative
DOR agonist activity of the methanol extract LC fractions of coll. no. 92553 FM.
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Experimental and Results
Our first step involved obtaining a source of aaptamine (2) for in vitro and in vivo
evaluation. Compounds 3-4 were obtained from the sponge Aaptos aaptos (coll. no. 92553)
but were devoid of 2. LC-MS analysis of sponge coll. no. 11308 (A. aaptos) indicated m/z
ions of 229 [M+H]+ consistent with that of 2 (not shown). We extracted coll. no. 11308
using a partition scheme shown in Fig. 2. The WB extract was enriched with 2 based on
LC-MS data in Fig. 3a and used to scale up it’s isolation by HPLC shown in Fig. 3b.
Chemical validation of pure 2 was confirmed by LC-MS and 1H NMR data in Fig. 4. This
allowed us to screen 2 alongside 3-4 and confirm it’s DOR activity in vitro (2, EC50 = 5.1;
3, EC50 = 4.1; 4, EC50 = 2.3). In vivo evaluation indicated 2 was an antidepressant in wild
type mice in the forced swim test (Fig. 5a, black bars) while having no effect on general
locomotion (Fig. 5b). We further found that the antidepressant activity was abolished in
genetically modified mice where the DOR gene was knocked out (Fig. 5a, red bars, DOR
KO). We also found 2 was an anxiolytic in the marble burying test (Fig. 5c). These results
indicate the anti-depressant activity previously reported for 2 is modulated by it’s agonist
activity of the delta opioid receptor.
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1) Scale up isolation of aaptamine (2) is best achieved through purification of water soluble extracts.
2) The mechanism of action for the in vivo anti-depressant-like and anxiolytic-like activity of 2
is mediated by it’s activity on the delta opioid receptor (DOR).
3) These data suggest that 2 can represent a novel chemical scaffold for the development of new
DOR ligands in neurobiological research.
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Figure 3. a) Analytical traces LC (top) MS (bottom) of coll. no. 11308 WB and
b) Preparative scale up HPLC traces of coll. no. 11308 WB fractions.
Gradient: 10%  100% CH3CN (45 min); [4.0 mg/100 µl] x 30 injections;
λmax = 254 nm; sensitivity = 2.0 AU; flow 2.0 ml/min.
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